# Epicentre: Phase 4 study in Ebola, Bundibugyo Virus Disease (BVD) (20000 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Epicentre |
| Sponsor type | Academic and hospital |
| Study | BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies |
| NCT ID | NCT07903350 |
| Phase | Phase 4 |
| Status | recruiting |
| Conditions | Ebola; Bundibugyo Virus Disease (BVD) |
| Intervention types | biological |
| Target enrollment | 20000 |
| Site countries | Democratic Republic of the Congo |
| Posted | 2026-10-29 |
| Planned start | 2026-09-19 |
| Event | Newly registered study |
| Event date | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- 20000 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07903350). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.